{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:40:28Z","timestamp":1792636828950,"version":"4.5.0"},"reference-count":69,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"DOI":"10.1080\/14656566.2026.2749641","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:08:15Z","timestamp":1791972495000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary systemic therapy of medullary thyroid cancer"],"prefix":"10.1080","author":[{"given":"Omar","family":"Abdel-Rahman","sequence":"first","affiliation":[{"name":"University of Alberta and Cross Cancer Institute","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19731-w"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad013"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003284"},{"key":"e_1_3_6_5_1","volume-title":"PDQ cancer information summaries [Internet]","year":"2002","unstructured":"PDQ Screening and Prevention Editorial Board. Thyroid cancer screening (PDQ\u00ae): health professional version. 2025 Apr 7. In: PDQ cancer information summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK453116\/"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.25318\/82-003-x202000100002-eng"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104766"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33654"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0185"},{"key":"e_1_3_6_10_1","unstructured":"Surveillance epidemiology and end results (seer) program SEER*Stat database: incidence - seer research data 12 registries (excl AK) Nov 2025 sub (1992\u20132023) - linked to county attributes - time dependent (1990\u20132024) income\/rurality 1969\u20132024 counties National Cancer Institute DCCPS surveillance research program released April 2026 based on the November 2025 submission."},{"key":"e_1_3_6_11_1","unstructured":"Ramos Santillan V Master SR Menon G et al. Medullary thyroid cancer. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Available from [cited 2026 May 31]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459354\/"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0312"},{"issue":"12","key":"e_1_3_6_13_1","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"The EGC","year":"2019","unstructured":"The EGC, Filetti S, Durante C, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30(12):1856\u20131883.","journal-title":"Ann Oncol"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0033"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.708949"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2703"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0207"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2092"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0056"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09836-x"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2023.4376"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.28194"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058984"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1314"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02790"},{"key":"e_1_3_6_27_1","unstructured":"[cited 2026 May 13]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-removes-risk-evaluation-and-mitigation-strategies-rems-caprelsa-vandetanib"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx479"},{"issue":"21","key":"e_1_3_6_30_1","article-title":"Phase ii study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr LL","year":"2010","unstructured":"Carr LL, Mankoff DA, Goulart BH, et al. Phase ii study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260\u20135268.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1127"},{"issue":"29","key":"e_1_3_6_32_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study","volume":"26","author":"Cohen EE","year":"2008","unstructured":"Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study. J Clin Oncol. 2008;26(29):4708\u20134713.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_6_33_1","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2015.0334","article-title":"Sorafenib for the treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysis","volume":"26","author":"de Castroneves LA","year":"2016","unstructured":"de Castroneves LA, Negr\u00e3o MV, de Freitas RM, et al. Sorafenib for the treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysis. Thyroid. 2016;26(3):414\u2013419.","journal-title":"Thyroid"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0068"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0363"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0291"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0224"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.599"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.006"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14395"},{"issue":"1","key":"e_1_3_6_43_1","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-Dependent resistance to selective ret inhibition in patients with ret fusion-positive lung cancer by combining selpercatinib with Crizotinib","volume":"27","author":"Rosen EY","year":"2021","unstructured":"Rosen EY, Johnson ML, Clifford SE, et al. Overcoming MET-Dependent resistance to selective ret inhibition in patients with ret fusion-positive lung cancer by combining selpercatinib with Crizotinib. Clin Cancer Res. 2021;27(1):34\u201342.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28848-x"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00053"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.010"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00563-4"},{"key":"e_1_3_6_48_1","unstructured":"[cited 2026 Oct 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/caprelsa-epar-product-information_en.pdf"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S127848"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0335"},{"key":"e_1_3_6_51_1","unstructured":"[cited 2026 Oct 5]. Available from: https:\/\/www.bccancer.bc.ca\/drug-database-site\/Drug%20Index\/Selpercatinib_monograph.pdf"},{"key":"e_1_3_6_52_1","unstructured":"[cited 2026 May 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05241834"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00630-y"},{"key":"e_1_3_6_54_1","unstructured":"[cited 2026 May 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04683250"},{"key":"e_1_3_6_55_1","unstructured":"[cited 2026 May 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04161391"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308795"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113507"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac574"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-026-00290-x"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002291"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2026.103032"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26527"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0506"},{"key":"e_1_3_6_66_1","unstructured":"[cited 2026 Oct 5]. Available from: https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/10507256251379060"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00116"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2749641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2749641","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2749641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:24:22Z","timestamp":1792635862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2749641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":69,"alternative-id":["10.1080\/14656566.2026.2749641"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2749641","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}